NASDAQ: SNYSanofi Stock
$53.42+3.00 (+5.95%)
Updated Jun 24, 2022
Sanofi shares are trading higher... find out Why SNY Price Moved with a free WallStreetZen account
Why Price MovedSNY Price
$53.42
Fair Value Price
$57.46
Market Cap
$135.00B
52 Week Low
$46.93
52 Week High
$58.10
P/E
18.92x
P/B
1.73x
P/S
2.82x
PEG
1.02x
Dividend Yield
3.36%
Revenue
$44.52B
Earnings
$7.07B
Gross Margin
68.7%
Operating Margin
20.8%
Profit Margin
15.9%
Debt to Equity
0.75
Operating Cash Flow
$12B
Beta
0.57
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Score
–
Industry Average (44)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SNY scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SNY ($53.42) is undervalued by 7.03% relative to our estimate of its Fair Value price of $57.46 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SNY ($53.42) is not significantly undervalued (7.03%) relative to our estimate of its Fair Value price of $57.46 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SNY ($53.42) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more SNY due diligence checks available for Premium users.
SNY News
Valuation
SNY fair value
Fair Value of SNY stock based on Discounted Cash Flow (DCF)
Price
$53.42
Fair Value
$57.46
Undervalued by
7.03%
SNY ($53.42) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SNY ($53.42) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SNY ($53.42) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SNY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
18.92x
Industry
9.02x
Market
20.48x
SNY is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
SNY is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
SNY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.73x
Industry
5.43x
SNY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SNY price to earnings growth (PEG)
For valuing profitable companies with growth potential
SNY is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
SNY's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
SNY's Earnings (EBIT) of $9.26B... subscribe to Premium to read more.
Interest Coverage Financials
SNY's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$136.6B
Liabilities
$58.2B
Debt to equity
0.75
SNY's short-term assets ($34.73B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SNY's short-term assets ($34.73B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SNY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SNY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
SNY's operating cash flow ($11.96B)... subscribe to Premium to read more.
Debt Coverage Financials
SNY vs General Drug Manufacturer Stocks
Sanofi Stock FAQ
©2022 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.